The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic <i>PIK3CA</i> Mutations

Abstract

CH5132799 is a selective class I PI3K inhibitor with potent antitumor activity against tumors harboring the PIK3CA mutations. Prediction of CH5132799 response on the basis of PIK3CA mutations could enable patient stratification in clinical settings.